The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review

Marta Krzysztofik; Paweł Brzewski; Aleksandra Kulbat; Magdalena Masajada; Karolina Richter; Wojciech M. Wysocki

doi:10.5114/ada.2024.143428

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2024
vol. 41

Send email

Copy url:

abstract:

Review paper

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review

Marta Krzysztofik

¹

,

Paweł Brzewski

^{1, 2}

,

Aleksandra Kulbat

^{3, 4}

,

Magdalena Masajada

^{1, 2}

,

Karolina Richter

²

,

Wojciech M. Wysocki

^{2, 3, 4}

Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, Krakow, Poland
Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
Department of Oncological Surgery, 5th Military Clinical Hospital, Krakow, Poland
National Institute of Oncology, Maria Sklodowska-Curie Memorial, Warsaw, Poland

Adv Dermatol Allergol 2024; XLI (6): 552–559

DOI: https://doi.org/10.5114/ada.2024.143428

Online publish date: 2024/10/04

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W. The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2024;41(6):552-559. doi:10.5114/ada.2024.143428.

APA

Krzysztofik, M., Brzewski, P., Kulbat, A., Masajada, M., Richter, K.,  & Wysocki, W. (2024). The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 41(6), 552-559. https://doi.org/10.5114/ada.2024.143428

Chicago

Krzysztofik, Marta, Paweł Brzewski, Aleksandra Kulbat, Magdalena Masajada, Karolina Richter,  and Wojciech M. Wysocki. 2024. "The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 41 (6): 552-559. doi:10.5114/ada.2024.143428.

Harvard

Krzysztofik, M., Brzewski, P., Kulbat, A., Masajada, M., Richter, K.,  and Wysocki, W. (2024). The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 41(6), pp.552-559. https://doi.org/10.5114/ada.2024.143428

MLA

Krzysztofik, Marta et al. "The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 41, no. 6, 2024, pp. 552-559. doi:10.5114/ada.2024.143428.

Vancouver

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W. The IL-23/Th17 pathway inhibitors in the treatment 
of psoriasis and the risk of skin malignancies: a review. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2024;41(6):552-559. doi:10.5114/ada.2024.143428.

Psoriasis and psoriatic arthritis are chronic inflammatory conditions that constitute a significant global health burden due to their prevalence and impact on quality of life. A deeper comprehension of psoriasis and psoriatic arthritis pathogenesis has recently led to the emergence of novel classes of biologics targeting the IL-23/Th17 pathway. The specific role of interleukin-12, -23, and -17 in cancer as either promoters or inhibitors is under investigation in various studies. Here, we explore the potential role of interleukin-12, -23, and -17 in the development of skin tumours as well as the safety of using their inhibitors in the treatment of psoriasis and psoriatic arthritis, particularly in relation to the risk of melanoma and non-melanoma skin cancer (NMSC) development.

keywords:

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review

Marta Krzysztofik 1 , Paweł Brzewski 1, 2 , Aleksandra Kulbat 3, 4 , Magdalena Masajada 1, 2 , Karolina Richter 2 , Wojciech M. Wysocki 2, 3, 4

psoriasis, psoriatic arthritis, melanoma, skin cancer, biologics, targeted therapies

Marta Krzysztofik

¹

,

Paweł Brzewski

^{1, 2}

,

Aleksandra Kulbat

^{3, 4}

,

Magdalena Masajada

^{1, 2}

,

Karolina Richter

²

,

Wojciech M. Wysocki

^{2, 3, 4}